Chutes & Ladders—AstraZeneca adds FDA cell and gene veteran

Longtime FDA leader Lola Fashoyin-Aje, M.D., is adapting to a new role at AstraZeneca as vice president and head of cell therapy regulatory science and strategy. Fashoyin-Aje is well-positioned to help the British pharma giant in this field, given she spent nearly 12 years at the FDA, with her tenure culminating in directing the clinical evaluation of cell and gene therapies.